Holen Sie sich die Stockscreener-App
43.05
1.62%
-0.71
Vorhandelsmarkt:
41.89
-1.16
-2.69%
Schlusskurs vom Vortag:
$43.76
Offen:
$44
24-Stunden-Volumen:
420.52K
Relative Volume:
0.70
Marktkapitalisierung:
$1.19B
Einnahmen:
$17.16M
Nettoeinkommen (Verlust:
$-163.62M
KGV:
-7.0806
EPS:
-6.08
Netto-Cashflow:
$-121.61M
1W Leistung:
+2.11%
1M Leistung:
+23.92%
6M Leistung:
+102.40%
1J Leistung:
+78.78%
1-Tages-Spanne:
$42.62
$45.32
1-Wochen-Bereich:
$40.01
$45.32
52-Wochen-Spanne:
$12.21
$45.32
Anaptysbio Inc Stock (ANAB) Company Profile
Firmenname
Anaptysbio Inc
Sektor
Branche
Telefon
858-362-6295
Adresse
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Vergleichen Sie ANAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
43.05 | 1.21B | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-06-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-19 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-03-12 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-02-26 | Eingeleitet | BTIG Research | Buy |
| 2024-02-21 | Eingeleitet | Stifel | Buy |
| 2024-02-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-22 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-13 | Herabstufung | Truist | Buy → Hold |
| 2022-09-01 | Eingeleitet | Raymond James | Outperform |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-03-16 | Hochstufung | Truist | Hold → Buy |
| 2021-03-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-10-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2019-11-08 | Herabstufung | SunTrust | Buy → Hold |
| 2019-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-04-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Bestätigt | Stifel | Buy |
| 2018-03-06 | Bestätigt | Stifel | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2018-01-23 | Bestätigt | Credit Suisse | Outperform |
| 2017-11-15 | Eingeleitet | SunTrust | Buy |
| 2017-11-09 | Eingeleitet | Jefferies | Buy |
| 2017-10-11 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten
AnaptysBio (NASDAQ:ANAB) Reaches New 1-Year HighHere's Why - MarketBeat
30,642 Shares in AnaptysBio, Inc. $ANAB Bought by XTX Topco Ltd - MarketBeat
Geode Capital Management LLC Sells 27,809 Shares of AnaptysBio, Inc. $ANAB - MarketBeat
Will AnaptysBio Inc. stock deliver consistent dividendsWeekly Stock Report & Daily Volume Surge Trade Alerts - Newser
AnaptysBio stock hits 52-week high at 43.35 USD - Investing.com
AnaptysBio Shares Navigate Legal Headwinds Amid Strong Performance - AD HOC NEWS
How institutional buying supports AnaptysBio Inc. stockMarket Performance Recap & Smart Money Movement Alerts - Newser
Why AnaptysBio Inc. (AN6) stock could break out in 2025Market Activity Recap & Real-Time Market Trend Scan - Newser
The Bull Case For AnaptysBio (ANAB) Could Change Following Jemperli Legal Clash With GSK Subsidiary - Yahoo Finance
Virtus Investment Advisers LLC Sells 6,909 Shares of AnaptysBio, Inc. $ANAB - MarketBeat
Jemperli Royalty Dispute Could Be a Game Changer for AnaptysBio (ANAB) - Sahm
Is AnaptysBio Inc. (AN6) stock a top hedge fund pickQuarterly Growth Report & Real-Time Market Sentiment Reports - Newser
What sentiment indicators say about AnaptysBio Inc. stockPortfolio Return Report & Entry and Exit Point Strategies - Newser
ANAB: AnaptyBio Among Top Quality Stocks with High Returns - GuruFocus
AnaptysBio, GSK's Tesaro Unit Likely Settle Jemperli Dispute Before July, Wedbush Says - MarketScreener
A Look at AnaptysBio's Valuation as Litigation With GSK Over Jemperli Royalties Draws Investor Focus - simplywall.st
Why AnaptysBio Inc. stock could rally in 2025Portfolio Update Report & AI Powered Buy and Sell Recommendations - BỘ NỘI VỤ
AnaptysBio FY2025 EPS Estimate Boosted by HC Wainwright - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
AnaptysBio Files Legal Complaint Against GSK and Tesaro - TipRanks
AnaptysBio's complaint against Tesaro for breaching agreement was publicly filed on Nov 26SEC filing - marketscreener.com
AnaptysBio files lawsuit against Tesaro and GSK over license deal - StreetInsider
AnaptysBio, Inc Files Lawsuit Against Tesaro and GSK - TradingView
Behavioral Patterns of ANAB and Institutional Flows - news.stocktradersdaily.com
What drives AnaptysBio Inc AN6 stock priceEconomic Data Impact & Rapid Portfolio Appreciation - earlytimes.in
Anaptys Announces Participation in December Investor Conferences - The Manila Times
AnaptysBio, Inc. to Participate in Upcoming Investor Conferences Featuring Leadership Team Insights - Quiver Quantitative
Wedbush Backs AnaptysBio As Buyback Eases Investor Fears - Finimize
AnaptysBio (NASDAQ:ANAB) Sets New 52-Week HighHere's What Happened - MarketBeat
AnaptysBio's (ANAB) Outperform Rating Reiterated at Wedbush - MarketBeat
HC Wainwright Issues Pessimistic Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price - MarketBeat
DCF Advisers LLC Purchases 13,150 Shares of AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio (Nasdaq: ANAB) to join Piper Sandler and Evercore investor conferences - Stock Titan
HC Wainwright & Co. Maintains AnaptysBio (ANAB) Buy Recommendation - Nasdaq
AnaptysBio stock hits 52-week high at 41.12 USD By Investing.com - Investing.com Nigeria
AnaptysBio stock hits 52-week high at 41.12 USD - Investing.com
GSK's TESARO sues AnaptysBio over alleged breach of cancer drug licence deal - Indian Pharma Post
ANAB: Wedbush Reiterates Outperform Rating and $50 Price Target - GuruFocus
Anaptys Announces $100 Million Stock Repurchase Plan - MarketScreener
AnaptysBio Presents Opportunity Despite 'Near-Term Turbulence' Amid Legal Dispute with GSK, Wedbush Says - marketscreener.com
AnaptysBio (ANAB) Analyst Rating Update: PT Lowered by HC Wainwr - GuruFocus
Is AnaptysBio Inc AN6 a good long term investmentShort Selling Opportunities & Double Or Triple Investment - earlytimes.in
ANAB Stock Falls After It Sues GSK Unit Tesaro Again, Claims Fresh Breach Of 2014 Deal - MSN
Share Buyback Program Declared by AnaptysBio (NASDAQ:ANAB) Board of Directors - MarketBeat
AnaptysBio Inc Stock Analysis and ForecastDebt-to-Equity Ratio Analysis & Double Or Triple Capital - earlytimes.in
Legal Battle Puts AnaptysBio's Jemperli Royalties At Risk - Finimize
AnaptysBio (NASDAQ:ANAB) Shares Gap DownTime to Sell? - MarketBeat
AnaptysBio (ANAB) Price Target Increased by 22.51% to 58.23 - MSN
AnaptysBio sets $100M stock repurchase plan - MSN
AnaptysBio expands stock repurchase plan by $100 million - Investing.com Nigeria
Tesaro and AnaptysBio Enter Legal Battle Over Suspected Breach in Contract - Pharmaceutical Executive
Finanzdaten der Anaptysbio Inc-Aktie (ANAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Anaptysbio Inc-Aktie (ANAB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| LOUMEAU ERIC J | CHIEF LEGAL OFFICER |
Sep 30 '25 |
Sale |
29.00 |
8,240 |
238,960 |
9,088 |
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):